Back to Browse Journals » Transplant Research and Risk Management » Volume 1 » Default

Managing hepatitis C in liver transplant patients with recurrent infection

Authors Tim Zimmermann, Gerd Otto, Marcus Schuchmann

Published Date September 2009 Volume 2009:1(Default) Pages 1—14

DOI http://dx.doi.org/10.2147/TRRM.S4615

Published 13 September 2009

Tim Zimmermann1, Gerd Otto2, Marcus Schuchmann1

1Department of Internal Medicine, 2Transplantation Surgery, University of Mainz, Germany

Abstract: Hepatitis C virus (HCV) reinfection after liver transplantation (LT) and recurrent hepatitis C often lead to recurrent cirrhosis (RC). RC is one of the most frequent complications resulting in organ failure and early death after LT in HCV-positive patients with reported 5-year rates from 20% to 40%. As HCV-cirrhosis is one of the leading indications for LT, the therapeutic management is a central issue. To date, the best available therapy is a combination of pegylated interferon + ribavirin in patients with established recurrent hepatitis C proven by liver biopsy. Although increasing experience in using interferon therapy after LT has suggested better response rates, treatment is limited by a poor tolerability and high rates of severe side effects, necessitating lower doses or withdrawal of therapy. The extent to which dose reductions and the concomitant administration of growth factors affect virological response or prevent complications is still to be determined. Prospective clinical trials are mandatory to identify the best time point and schedule of antiviral treatment in transplant patients. Currently, therapeutic options need to be discussed for each individual patient. Therefore therapy should be carried out only in transplant centers with experience in managing hepatitis C after LT.

Keywords: hepatitis C, liver transplantation, recurrent infection, treatment

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Novel nanostructured biomaterials: implications for coronary stent thrombosis

Karagkiozaki V, Karagiannidis PG, Kalfagiannis N, Kavatzikidou P, Patsalas P, Georgiou D, Logothetidis S

International Journal of Nanomedicine 2012, 7:6063-6076

Published Date: 17 December 2012

Liposome mitigation of curcumin inhibition of cardiac potassium delayed-rectifier current

Helson L, Shopp G, Bouchard A, Majeed M

Journal of Receptor, Ligand and Channel Research 2012, 5:1-8

Published Date: 16 November 2012

Retrospective review of bone mineral metabolism management in end-stage renal disease patients wait-listed for renal transplant

Chavlovski A, Knoll GA, Ramsay T, Hiremath S, Zimmerman DL

Transplant Research and Risk Management 2012, 4:25-30

Published Date: 5 September 2012

Natural material adsorbed onto a polymer to enhance immune function

Reinaque AP, França EL, Scherer EF, Côrtes MA, Souto FJ, Honorio-França AC

Drug Design, Development and Therapy 2012, 6:209-216

Published Date: 27 August 2012

Quality of life and baseline characteristics associated with depressive symptoms among patients with heart disease

Rejai S, Giardino ND, Krishnan S, Ockene IS, Rubenfire M, Jackson EA

Clinical Epidemiology 2012, 4:181-186

Published Date: 24 July 2012

Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial

Fong R, Leitritz M, Siou-Mermet R, Erb T

Clinical Ophthalmology 2012, 6:1113-1124

Published Date: 18 July 2012

Keratouveitis from Euphorbia cyparissias exposure is a temporal phenomenon

Fleischman D, Meyer JJ, Fowler WC

Clinical Ophthalmology 2012, 6:851-853

Published Date: 1 June 2012

Nanoparticles and cancer therapy: A concise review with emphasis on dendrimers

Dhruba J Bharali, Marianne Khalil, Mujgan Gurbuz, Tessa M Simone, Shaker A Mousa

International Journal of Nanomedicine 2009, 4:1-7

Published Date: 20 January 2009